PIK3CA and breast cancer: Indeed, preclinical and clinical data support the argument that patients harboring these mutations could potentially benefit from specific therapeutic trials, such as BOLERO-1 and BOLERO-3 trials in breast cancer patients with PIK3CA mutations [29].